Citius Oncology, Inc. - Common Stock (CTOR)

About Citius Oncology, Inc. - Common Stock (CTOR)

Citius Oncology, Inc. is a pharmaceutical company, which engages in developing and commercializing targeted oncology therapies. Its lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. The company was founded on March 1, 2021 and is headquartered in Cranford, NJ.

Citius Oncology, Inc. - Common Stock News